While overall MACE risk was similar for both agents, risk gradients by eGFR differed: liraglutides cardiovascular risk increased as kidney function declined ( p for trend = 0.0079), whereas dulaglutide maintained a stable risk profile across CKD stages ( p = 0.19)
None of these mechanisms directly target appetite, fat metabolism, or caloric regulation
They put it on a list called S0: "Non-Approved Substances." It is the category for things that no health authority, anywhere in the world, has approved for use in humans
Vial headspace management affects oxidation rates at room temperature
Reference Mortimer, Goecks, Kacsoh, Mobley, Bowersock, Taylor and Schlenke2013)
Heres What You Need to Do If youre currently taking a GLP-1 or considering it, its not all doom and gloom